Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
Strength Seen in OptimizeRx (OPRX): Can Its 7.5% Jump Turn into More Strength?
OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story
OptimizeRx's Q3 2025 results reinforce my long-term bullish thesis. OPRX demonstrates continued operational momentum, supporting confidence in sustained growth. Recent earnings solidify conviction in the company's strategic positioning and execution.
OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript
OptimizeRx Corporation ( OPRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Stephen Silvestro - President & CEO Edward Stelmakh - Chief Financial & Strategic Officer Andrew D'Silva - Chief Business Officer Conference Call Participants Ryan Daniels - William Blair & Company L.L.C., Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division Eric Martinuzzi - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B.
OptimizeRx Corp. (OPRX) Tops Q3 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago.
OptimizeRx: How The Stock Is Changing Pharma Marketing
OptimizeRx Corporation is evolving from an EHR messaging platform to a clinical data and AI-driven advertising company, leveraging DAAP and MNT technologies. Q2 2025 financials show strong revenue growth, improved margins, and a shift to higher-margin subscription revenues, supporting management's raised guidance for 2025. The Lamar partnership and expanding mid-tier pharma client base diversify revenue streams, reduce risk, and confirm OPRX's strategic pivot to broader advertising markets.
OptimizeRx Bets on AI and Workflow Integration - Will This Pay Off?
OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.
All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy
OptimizeRx (OPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew Jacob D'Silva - Senior Vice President of Corporate Finance Edward Stelmakh - CFO & COO Stephen L. Silvestro - President & CEO Conference Call Participants Anderson Schock - B.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Bull Of The Day: OptimizeRX (OPRX)
This stock is reporting earnings next week and posting positive operating margins is going to be key.
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
OptimizeRx OPRX is carving out a secure niche in the increasingly crowded HealthTech landscape, signaling a developing moat anchored in scale, data and execution. Over the previous two quarters, the company has posted double-digit top-line growth.
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
